Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Breast Cancer Stage IV”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT04896320
What this trial is testing

Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.

Who this might be right for
Breast Cancer Stage IV
Providence Health & Services
Early research (Phase 1)Study completedNCT01772004
What this trial is testing

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Who this might be right for
Solid Tumors
EMD Serono Research & Development Institute, Inc. 1,756
Large-scale testing (Phase 3)Study completedNCT00047255
What this trial is testing

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Jonsson Comprehensive Cancer Center 263
Early research (Phase 1)UnknownNCT00002616
What this trial is testing

Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
University of Illinois at Chicago 36
Large-scale testing (Phase 3)UnknownNCT01126138
What this trial is testing

Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

Who this might be right for
Carcinoma, Invasive Ductal, Breast
Chinese Academy of Medical Sciences 200
Early research (Phase 1)Study completedNCT01281150
What this trial is testing

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Adult Solid NeoplasmEstrogen Receptor NegativeEstrogen Receptor Positive+8 more
National Cancer Institute (NCI) 22
Early research (Phase 1)Ended earlyNCT00634088
What this trial is testing

Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
R-Pharm 13
Large-scale testing (Phase 3)Looking for participantsNCT06954961
What this trial is testing

Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
InventisBio Co., Ltd 640
Early research (Phase 1)Study completedNCT00327288
What this trial is testing

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

Who this might be right for
Non-small Cell Lung CancerBreast CancerProstate Cancer
AmpliMed Corporation 34
Not applicableApproved For MarketingNCT01240421
What this trial is testing

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Who this might be right for
Metastatic Breast Cancer
Eisai Inc.
Large-scale testing (Phase 3)Study completedNCT02514681
What this trial is testing

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer

Who this might be right for
HER2-positive Locally Advanced or Metastatic Breast Cancer
Japan Breast Cancer Research Group 226
Large-scale testing (Phase 3)Study completedNCT00876395
What this trial is testing

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 719
Testing effectiveness (Phase 2)Active Not RecruitingNCT03393845
What this trial is testing

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Nancy Chan, MD 47
Large-scale testing (Phase 3)Looking for participantsNCT07085767
What this trial is testing

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Who this might be right for
Breast CancerLocally Advanced Breast CancerMetastatic Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 1,000
Testing effectiveness (Phase 2)Ended earlyNCT00852332
What this trial is testing

Docetaxel With or Without a Phytochemical in Treating Patients With Breast Cancer

Who this might be right for
Breast Cancer
Centre Jean Perrin 42
Testing effectiveness (Phase 2)UnknownNCT04304352
What this trial is testing

Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients

Who this might be right for
Advanced Breast Cancer
European Institute of Oncology 162
Not applicableStudy completedNCT04987931
What this trial is testing

Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 84
Testing effectiveness (Phase 2)Ended earlyNCT01185509
What this trial is testing

Trastuzumab and Vinorelbine in Advanced Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 31
Testing effectiveness (Phase 2)WithdrawnNCT05212701
What this trial is testing

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

Who this might be right for
FatigueLocally Advanced or Metastatic Breast Cancer
Dompé Farmaceutici S.p.A
Not applicableStudy completedNCT00477919
What this trial is testing

E-MOSAIC Electronic Tool to Monitor Symptoms

Who this might be right for
Cancer
Swiss Cancer Institute 264
Next Page